Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets

You may also be interested in...



Mindray Jumps Into Orthopedic Space With Sixth Acquisition In Last 18 Months

China’s leading medical device company enters the orthopedic market with a $35.5 million acquisition of domestic player Dragonbio.

China’s Mindray Expands Market With Increased R&D And Acquisitions

Mindray expects to hold its own amidst foreign competition, including in the high-end device market thanks to acquisitions and R&D investments that have boosted its technological capability.

Facing Tougher Competition At Home, China's Mindray Should Target Global Mid- To High-end Market, Analysts Say

Facing a new round of marketing campaigns from international device makers targeting China's low- to mid-end hospital markets, Shenzhen based Mindray Medical will be better off focusing instead on mid- to high-end global markets to stay competitive, analysts say

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel